1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
REMEDI Inc.

REMEDI Inc.

KKRX:387690
12,710.00
KRW
-1,400.00
(-9.92%)
291.05EPS
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
33.93
508.29
674.52
1,220.8
1,083.23
2,105.62
2,289.02
Basic EPS, GAAP
-26.3
-346
-267
73
-573
142
777
Free Cash Flow per Basic Share
-58.81
-425.36
-637.3
-796.5
-916.97
356.29
-466
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
65.22
401.49
652.75
1,114.78
655
792.68
1,448.4
Tangible Book Value per Share
65.22
325.7
536.73
934.35
596.99
751.03
1,422.75
Basic Weighted Avg Shares
60
5
6
6
6
6
6
Sales/Revenue/Turnover
2,030
2,665
4,032
7,691
6,918
13,441
14,628
Operating Margin (%)
-75.57
-42.53
-28.56
2.3
-33.52
7.02
18.8
Depreciation Expense
149
219
547
654
758
805
806
Net Income, GAAP
-1,573
-1,814
-1,596
460
-3,659
906
4,965
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-77.52
-68.07
-39.58
5.98
-52.9
6.74
33.94
Working Capital
339
1,056
1,603
2,579
-1,591
-1,264
2,325
LT Debt
1,992
1,598
2,813
3,824
4,432
3,147
4,774
Total Equity
497
3,062
4,978
8,501
4,995
5,870
11,078
Return on Invested Capital (%)
- -
- -
- -
1.65
- -
6.59
- -
Return on Capital (%)
- -
- -
- -
4.27
- -
9.74
- -
Return on Common Equity (%)
- -
-101.95
-39.7
6.82
-54.23
16.42
58.11

Capital Structure

KRW

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

KRW

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
39.67%
88.73%
Free Cash Flow
- -
-50.11%
-230.94%
Net Income, GAAP
- -
-142.71%
447.79%
Sales/Revenue/Turnover
- -
47.02%
8.83%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
13,441
2025
3,870
3,837
- -
- -
14,628
2026
9,383
6,184
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
142
2025
-68
27
- -
- -
777
2026
439
292
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Bong-Ho Jo
Sector
Health technology
Industry
Medical specialties
Address
Chuncheon-si South Korea
IPO Date
Jul 13, 2026
Website
remedihc.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
REMEDI Inc. is a South Korea-based medical device manufacturer specializing in portable diagnostic X-ray imaging solutions and electromagnetic therapeutic equipment. Founded in 2012 and headquartered in Wonju, South Korea, the company operates across two primary business divisions: Diagnostic Imaging Systems and Electromagnetic Therapy Devices. The company's core product portfolio includes handheld and portable dental X-ray systems under the REMEX series, such as the REMEX-T100 and REMEX-KA6, utilized for intraoral digital radiography in clinical and field environments; mobile and portable medical diagnostic X-ray devices, including the REMEX-G01, designed for point-of-care diagnostics, emergency response, intensive care units, military medicine, and veterinary clinics; Transcranial Magnetic Stimulation (TMS) therapeutic systems, such as the ALTMS series, engineered for non-invasive neuromodulation and the treatment of neurological and psychiatric disorders; and related medical imaging accessories, software, and electromagnetic therapy apparatus. REMEDI Inc. markets its products globally to hospitals, dental practices, emergency medical providers, and specialized healthcare clinics across North America, Europe, Asia-Pacific, Latin America, and the Middle East through direct sales, authorized distributors, and OEM/ODM partnerships. In recent developments, the company has broadened its international commercial presence by securing key global regulatory clearances, including United States FDA 510(k) clearances and European CE marks for its upgraded portable radiography systems, while actively expanding its distribution network across North America and Europe, and investing in the development and commercialization of next-generation lightweight portable digital X-ray technologies.